IMGN Financial Facts
Clinical materials reimbursement: 46KResearch and development support: 1.35M
See Full Income Statement
Deferred revenue, net of current portion: 19.16M
Cash and cash equivalents: 196M
See Full Balance Sheet
Immunogen Inc. (IMGN) Earnings
|
Expand Research on IMGN
Next EPS Date | 4/25/24 *Est. | EPS Growth Rate | N/A |
---|---|---|---|
Average EPS % Beat Rate | +73.5% | Revenue Growth Rate | N/A |
Average % Move 1-Wk after EPS | +51.9% | Normal Earnings Time | Before Open |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
8/1/14 | Q414 | -$0.83 | -$0.32 | -$0.51 | $5.74M | $9.72M | N/A | Details | |||
11/3/17 | Q317 | -$0.61 | -$0.19 | -$0.42 | $8.5M | $33.62M | = | Details | |||
7/31/15 | Q415 | -$0.71 | -$0.35 | -$0.36 | $12.61M | $15.42M | N/A | Details | |||
2/25/22 | Q421 | -$0.17 | N/A | N/A | $28M | $85.8M | = | Details | |||
4/25/14 | Q314 | -$0.44 | -$0.27 | -$0.17 | $6.9M | $13.28M | = | Details | |||
2/12/24 | Q423 | N/A | $0.13 | N/A | N/A | $129.48M | N/A | N/A | N/A | ||
10/28/16 | Q117 | -$0.51 | -$0.38 | -$0.13 | $7.66M | $21.12M | = | Details | |||
2/9/24 | Q423 | N/A | $0.13 | N/A | N/A | $129.48M | N/A | N/A | N/A |